Mechanisms of HIV-1 integrase resistance to dolutegravir and potent inhibition of drug-resistant variants
Science Advances · 21.07.2023 · 9 (29)
DOI: 10.1126/sciadv.adg5953 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 21.07.2023. Verfasst von Min Li und 18 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Diabetes and Digestive Diseases, National Institutes of Health, Bethesda, MD, 20892, USA. Hauptthemen laut MEDLINE: HIV Integrase Inhibitors, HIV Integrase. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 88 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NIAID NIH HHS, NIH HHS.
Abstract (Originalsprache)
HIV-1 infection depends on the integration of viral DNA into host chromatin. Integration is mediated by the viral enzyme integrase and is blocked by integrase strand transfer inhibitors (INSTIs), first-line antiretroviral therapeutics widely used in the clinic. Resistance to even the best INSTIs is a problem, and the mechanisms of resistance are poorly understood. Here, we analyze combinations of the mutations E138K, G140A/S, and Q148H/K/R, which confer resistance to INSTIs. The investigational drug 4d more effectively inhibited the mutants compared with the approved drug Dolutegravir (DTG). We present 11 new cryo-EM structures of drug-resistant HIV-1 intasomes bound to DTG or 4d, with better than 3-Å resolution. These structures, complemented with free energy simulations, virology, and enzymology, explain the mechanisms of DTG resistance involving E138K + G140A/S + Q148H/K/R and show why 4d maintains potency better than DTG. These data establish a foundation for further development of INSTIs that potently inhibit resistant forms in integrase.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- National Institute of Diabetes and Digestive Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
- The Salk Institute for Biological Studies, La Jolla, CA, 92037, USA.
- Center for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, MD, 21702, USA.
- Center for Biophysics and Computational Biology, and Department of Chemistry, Temple University, Philadelphia, PA 19122, USA.
- Center for Biophysics and Computational Biology and Department of Physics, Temple University, Philadelphia, PA 19122, USA.
- Department of Chemistry and Physical Sciences, Pace University, New York, NY, 10038, USA.
ORCID-Profile: Min Li, Dario Oliveira Passos, Zelin Shan, Steven J Smith, Qinfang Sun, Avik Biswas, Indrani Choudhuri, Timothy S Strutzenberg, Allan Haldane, Nanjie Deng, Xue Zhi Zhao, Lorenzo Briganti, Mamuka Kvaratskhelia, Terrence R Burke, Ronald M Levy, Stephen H Hughes, Robert Craigie, Dmitry Lyumkis
Förderung
- NIGMS NIH HHS
- NIAID NIH HHS
- NIH HHS
Zitieren
APA
Li, M., Oliveira Passos, D., Shan, Z., Smith, S. J., Sun, Q., Biswas, A., Choudhuri, I., Strutzenberg, T. S., Haldane, A., Deng, N., Li, Z., Zhao, X. Z., Briganti, L., Kvaratskhelia, M., Burke, T. R., Levy, R. M., Hughes, S. H., Craigie, R., & Lyumkis, D. (2023). Mechanisms of HIV-1 integrase resistance to dolutegravir and potent inhibition of drug-resistant variants. Science Advances, 9(29). https://doi.org/10.1126/sciadv.adg5953
Vancouver
Li M, Oliveira Passos D, Shan Z, Smith SJ, Sun Q, Biswas A, et al. Mechanisms of HIV-1 integrase resistance to dolutegravir and potent inhibition of drug-resistant variants. Science Advances. 2023;9(29). doi:10.1126/sciadv.adg5953
BibTeX
@article{Li2023,
author = {Li, Min and Oliveira Passos, Dario and Shan, Zelin and Smith, Steven J and Sun, Qinfang and Biswas, Avik and Choudhuri, Indrani and Strutzenberg, Timothy S and Haldane, Allan and Deng, Nanjie and Li, Zhaoyang and Zhao, Xue Zhi and Briganti, Lorenzo and Kvaratskhelia, Mamuka and Burke, Terrence R and Levy, Ronald M and Hughes, Stephen H and Craigie, Robert and Lyumkis, Dmitry},
title = {Mechanisms of HIV-1 integrase resistance to dolutegravir and potent inhibition of drug-resistant variants},
journal = {Science Advances},
year = {2023},
volume = {9},
number = {29},
doi = {10.1126/sciadv.adg5953}
}
EUVIMED